Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD )

2.300 -1.420 (-38.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,531,007
Open 3.300
Bid (Size) 2.350 (49)
Ask (Size) 2.360 (1)
Prev. Close 3.720
Today's Range 2.250 - 3.400
52wk Range 2.250 - 15.70
Shares Outstanding 160,028,388
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill

Performance

YTD
-46.88%
-46.88%
1 Month
-47.49%
-47.49%
3 Month
-44.58%
-44.58%
6 Month
-66.33%
-66.33%
1 Year
-83.33%
-83.33%

More News

Read More
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Earnings Preview: Ironwood Pharmaceuticals
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.